Antengene (HKSE:06996) FCF Margin % : 4,506.48% (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Antengene FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Antengene's Free Cash Flow for the six months ended in Dec. 2023 was HK$-232.22 Mil. Antengene's Revenue for the six months ended in Dec. 2023 was HK$-5.15 Mil. Therefore, Antengene's FCF Margin % for the quarter that ended in Dec. 2023 was 4,506.48%.

As of today, Antengene's current FCF Yield % is -155.84%.

The historical rank and industry rank for Antengene's FCF Margin % or its related term are showing as below:

HKSE:06996' s FCF Margin % Range Over the Past 10 Years
Min: -2182.69 Med: -1157.22 Max: -419.37
Current: -1157.22

During the past 6 years, the highest FCF Margin % of Antengene was -419.37%. The lowest was -2182.69%. And the median was -1157.22%.

HKSE:06996's FCF Margin % is ranked worse than
78.08% of 1040 companies
in the Biotechnology industry
Industry Median: -137.43 vs HKSE:06996: -1157.22

Antengene FCF Margin % Historical Data

The historical data trend for Antengene's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Antengene FCF Margin % Chart

Antengene Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-2,182.69

-419.37

-1,157.22

Antengene Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
FCF Margin %	Get a 7-Day Free Trial						-1,390.29	-514.93	-370.81	-786.71	4,506.48

Competitive Comparison of Antengene's FCF Margin %

For the Biotechnology subindustry, Antengene's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Antengene's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Antengene's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Antengene's FCF Margin % falls into.

Antengene FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Antengene's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-851.911	/	73.617
	=	-1,157.22 %

Antengene's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-232.219	/	-5.153
	=	4,506.48 %

Antengene FCF Margin % Related Terms

Thank you for viewing the detailed overview of Antengene's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Antengene (HKSE:06996) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Antengene Corp Ltd (HKSE:06996) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

1065 West Zhongshan Road, Suites 1206-1209, Block B, Zhongshan SOHO Plaza, Changning District, Shanghai, CHN

Website

https://www.antengene.com

Antengene Corp Ltd is a clinical-stage biopharmaceutical company focused on oncology medicines. The company produces drugs such as selinexor, eltanexor, verdinexor, and other products. It also engages in the discovery, development, manufacturing, and commercialization of first-in-class therapeutics for the treatment of hematologic malignancies and solid tumors. Geographically it operates in China and other regions.

Executives

Jay Mei 2023 Grat	2201 Interest of corporation controlled by you
Mei Jay	2201 Interest of corporation controlled by you
Begonia Investment Ltd.	2101 Beneficial owner
Qiming Corporate Gp V, Ltd.
The Core Trust Company Limited	2301 Trustee
Tct (bvi) Limited	2501 Other
Fountainvest China Capital Partners Gp3 Ltd.	2201 Interest of corporation controlled by you
Fountainvest China Capital Partners Fund Iii, L.p.	2201 Interest of corporation controlled by you
Fmr Llc	2201 Interest of corporation controlled by you
Fidelity Investment Trust	2101 Beneficial owner
Jay Mei 2020 Grat	2201 Interest of corporation controlled by you
Meiland Pharma Tech Spc
Boyu Capital Group Holdings Ltd	2201 Interest of corporation controlled by you
Boyu Capital General Partner Iii, Ltd
Boyu Capital General Partner Iii, L.p.

Antengene (HKSE:06996) Headlines

No Headlines